OnCusp Therapeutics is a Biotech company. It has raised $139M in total funding. Backed by Novo Holdings, OrbiMed, F-Prime Capital.
OnCusp Therapeutics funding overview
OnCusp Therapeutics is a Biotech company. OnCusp Therapeutics has raised $139M in total disclosed funding. That places its disclosed total in the $100M–$250M range. The round record for OnCusp Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Novo Holdings, OrbiMed, F-Prime Capital, Sofinnova Investments, Catalio Capital Management, Marshall Wace and 4 others. 10 distinct backers are named across the disclosed rounds.
OnCusp Therapeutics at a glance
Total raised
$139M
Latest round date
January 2024
Industry
Biotech
Notable investors
Novo Holdings, OrbiMed, F-Prime Capital, Sofinnova Investments, Catalio Capital Management, Marshall Wace, Forge Life Science Partners, Blackbird BioVentures
Frequently asked about OnCusp Therapeutics funding
How much has OnCusp Therapeutics raised?
OnCusp Therapeutics has raised $139M in total disclosed funding across the rounds on record.
Who has invested in OnCusp Therapeutics?
Novo Holdings, OrbiMed, F-Prime Capital, Sofinnova Investments, Catalio Capital Management, Marshall Wace are named among the investors backing OnCusp Therapeutics.
What was the latest OnCusp Therapeutics funding round?
No round stage has been disclosed for OnCusp Therapeutics.
Where is OnCusp Therapeutics based?
No headquarters location is disclosed for OnCusp Therapeutics.
What sector does OnCusp Therapeutics operate in?
OnCusp Therapeutics is tracked under Biotech, with $139M in disclosed funding.
When did OnCusp Therapeutics last raise?
The last disclosed OnCusp Therapeutics round closed in January 2024.
OnCusp Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies below to benchmark round size and investor mix.
